All In Biotech

Drug Trial Radar · NCT00151515

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males

Last checked: Nov 20, 2026Latest source record: Sep 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

352

Actual

Start

Oct 2003

Primary completion

Jul 2004

Study completion Jul 2004

Sponsor

Lead sponsor
Johnson & Johnson Consumer and Personal Products WorldwideJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 15 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.

Conditions

  • Androgenetic Alopecia

Interventions

  • minoxidilDrug

    Topical 5% minoxidil foam, BID, for sixteen weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in non-vellus hair count in the target region as determined by validated computer-assisted dot-mapping technique and subject ratingsTime frame: Baseline to 16 Weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    Vallejo, California

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    New Haven, Connecticut

  • Pfizer Investigational Site

    Fridley, Minnesota

  • Pfizer Investigational Site

    Minneapolis, Minnesota

  • Pfizer Investigational Site

    Durham, North Carolina

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Cleveland, Ohio

  • Pfizer Investigational Site

    Portland, Oregon

  • Pfizer Investigational Site

    Hershey, Pennsylvania

  • Pfizer Investigational Site

    Austin, Texas

  • Pfizer Investigational Site

    Dallas, Texas

  • Pfizer Investigational Site

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.